Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 18 |
| List of Tables | 9 | 8 |
| List of Figures | 17 | 4 |
| Immunomodulators Market to 2017 - Market Introduction | 21 | 2 |
| GBI Research Report Guidance | 21 | 2 |
| Immunomodulators Market to 2017 - Market Characterization | 23 | 8 |
| Classification | 23 | 1 |
| Immunosuppressants | 23 | 1 |
| Immunostimulants | 23 | 1 |
| Drivers and Barriers | 24 | 1 |
| Global Immunomodulators Market Drivers | 24 | 1 |
| Gradual Growth in the Uptake of MAbs to Drive the Immunomodulators Market | 24 | 1 |
| Expanded Indications and Improved Side-effect and Tolerance Profiles to Open up New Antibody Therapy Patient Group | 24 | 1 |
| Cancer and HIV/AIDS Vaccines hold Significant Potential for the Future | 25 | 1 |
| Reduced Risk of Co-morbidity and Transplant Rejection to Drive the Calcineurin Market | 25 | 1 |
| Global Immunomodulators Market Restraints | 25 | 1 |
| High Cost of Biologics Hampering the Growth of the Treatment Population | 25 | 1 |
| Adverse Effects from Prolonged Use of Glucocorticoids are Slowing Growth | 25 | 1 |
| Industry Challenges - Majority of mAbs Receive Approvals as Last Option Therapies | 26 | 1 |
| Unmet Needs | 26 | 1 |
| High Cost of Biologic Therapies Responsible for Low Patient Usage | 26 | 1 |
| MAbs Unable to Provide a Disease Cure | 26 | 1 |
| Revenue Forecast - Global | 27 | 1 |
| Revenue | 27 | 2 |
| Annual Cost of Therapy | 29 | 1 |
| Prescription Population | 30 | 1 |
| Immunomodulators Market to 2017 - Geographical Landscape | 31 | 3 |
| The US | 31 | 1 |
| Revenue | 31 | 1 |
| Europe | 32 | 1 |
| Revenue | 32 | 1 |
| ROW | 33 | 1 |
| Revenue | 33 | 1 |
| Immunomodulators Market to 2017 - Immunosuppressants | 34 | 2 |
| Introduction | 34 | 1 |
| Drug Classes | 34 | 1 |
| Applications | 34 | 1 |
| Global Market Size | 35 | 1 |
| Immunosuppressants - Antibodies | 36 | 18 |
| Introduction | 36 | 1 |
| Prescription Population | 37 | 1 |
| Global | 37 | 1 |
| The US | 38 | 1 |
| Europe | 39 | 1 |
| ROW | 40 | 1 |
| Annual Cost of Therapy | 41 | 1 |
| Global | 41 | 1 |
| The US | 42 | 1 |
| Europe | 43 | 2 |
| ROW | 45 | 1 |
| Revenue | 46 | 1 |
| Global | 46 | 1 |
| The US | 47 | 1 |
| Europe | 48 | 1 |
| ROW | 49 | 1 |
| Pipeline Molecules | 50 | 1 |
| Phase III | 50 | 1 |
| Phase II | 51 | 1 |
| Phase I | 52 | 1 |
| Preclinical/Discovery Phase | 52 | 2 |
| Immunosuppressants - Interferon Beta | 54 | 15 |
| Introduction | 54 | 1 |
| Prescription Population | 54 | 1 |
| Global | 54 | 2 |
| The US | 56 | 1 |
| Europe | 57 | 1 |
| ROW | 58 | 1 |
| Annual Cost of Therapy | 59 | 1 |
| Global | 59 | 1 |
| The US | 60 | 1 |
| Europe | 61 | 1 |
| ROW | 62 | 1 |
| Revenue | 63 | 1 |
| Global | 63 | 1 |
| The US | 64 | 1 |
| Europe | 65 | 1 |
| ROW | 66 | 1 |
| Pipeline Molecules | 67 | 1 |
| Phase III | 67 | 1 |
| Phase II | 67 | 1 |
| Phase I | 67 | 1 |
| Preclinical/Discovery Phase | 68 | 1 |
| Immunosuppressants - Glucocorticoids | 69 | 39 |
| Introduction | 69 | 1 |
| Therapeutic Indications | 69 | 1 |
| Immunological Mode of Action | 69 | 1 |
| Immunosuppression | 69 | 1 |
| Anti-inflammatory | 70 | 1 |
| Prescription Population | 71 | 1 |
| Global | 71 | 1 |
| The US | 72 | 1 |
| Europe | 73 | 1 |
| ROW | 74 | 1 |
| Annual Cost of Therapy | 75 | 1 |
| Global | 75 | 1 |
| The US | 76 | 1 |
| Europe | 77 | 1 |
| ROW | 78 | 1 |
| Revenue | 79 | 1 |
| Global | 79 | 1 |
| The US | 80 | 1 |
| Europe | 81 | 1 |
| ROW | 82 | 1 |
| Pipeline Molecules | 83 | 1 |
| Phase III | 83 | 7 |
| Phase II | 90 | 16 |
| Phase I | 106 | 1 |
| Preclinical/Discovery Phase | 107 | 1 |
| Immunosuppressants - Calcineurin Inhibitors | 108 | 33 |
| Introduction | 108 | 1 |
| Prescription Population | 108 | 1 |
| Global | 108 | 2 |
| The US | 110 | 1 |
| Europe | 111 | 1 |
| ROW | 112 | 1 |
| Annual Cost of Therapy | 113 | 1 |
| Global | 113 | 1 |
| The US | 114 | 1 |
| Europe | 115 | 1 |
| ROW | 116 | 1 |
| Revenue | 117 | 1 |
| Global | 117 | 1 |
| The US | 118 | 1 |
| Europe | 119 | 1 |
| ROW | 120 | 1 |
| Pipeline Molecules | 121 | 1 |
| Phase III | 121 | 1 |
| Phase II | 122 | 15 |
| Phase I | 137 | 3 |
| Preclinical/Discovery | 140 | 1 |
| Immunosuppressants - Antimetabolites | 141 | 52 |
| Introduction | 141 | 1 |
| Prescription Population | 141 | 1 |
| Global | 141 | 1 |
| The US | 142 | 2 |
| Europe | 144 | 1 |
| ROW | 145 | 1 |
| Annual Cost of Therapy | 146 | 1 |
| Global | 146 | 1 |
| The US | 147 | 1 |
| Europe | 148 | 1 |
| ROW | 149 | 1 |
| Revenue | 150 | 1 |
| Global | 150 | 1 |
| The US | 151 | 1 |
| Europe | 152 | 1 |
| ROW | 153 | 1 |
| Pipeline Molecules | 154 | 1 |
| Phase III | 154 | 6 |
| Phase II | 160 | 19 |
| Phase I | 179 | 8 |
| Preclinical/Discovery Phase | 187 | 6 |
| Immunomodulators Market to 2017 - Immunostimulants | 193 | 2 |
| Introduction | 193 | 1 |
| Drug Classes | 193 | 1 |
| Applications | 193 | 1 |
| Global Market Size | 194 | 1 |
| Immunostimulants - Vaccines, Active Immunity | 195 | 19 |
| Introduction | 195 | 1 |
| Target Population | 196 | 1 |
| Revenue | 197 | 1 |
| Global | 197 | 1 |
| The US | 198 | 2 |
| Europe | 200 | 1 |
| ROW | 201 | 1 |
| Pipeline Molecules | 202 | 1 |
| NDA Filed | 202 | 1 |
| Phase III | 203 | 3 |
| Phase II | 206 | 3 |
| Phase I | 209 | 1 |
| Preclinical/Discovery Phase | 210 | 4 |
| Immunostimulants: Antibodies - Passive Immunity | 214 | 25 |
| Introduction | 214 | 1 |
| Prescription Population | 214 | 1 |
| Global | 214 | 2 |
| The US | 216 | 1 |
| Europe | 217 | 1 |
| ROW | 218 | 1 |
| Annual Cost of Therapy | 219 | 1 |
| Global | 219 | 1 |
| The US | 220 | 1 |
| Europe | 221 | 1 |
| ROW | 222 | 1 |
| Revenue | 223 | 1 |
| Global | 223 | 1 |
| The US | 224 | 1 |
| Europe | 225 | 1 |
| ROW | 226 | 1 |
| Pipeline Molecules | 227 | 1 |
| NDA Filed | 227 | 1 |
| Phase III | 227 | 2 |
| Phase II | 229 | 6 |
| Phase I | 235 | 2 |
| Preclinical/Discovery Phase | 237 | 2 |
| Immunostimulants: Interferon Alpha - Passive Immunity | 239 | 22 |
| Introduction | 239 | 1 |
| Prescription Population | 240 | 1 |
| Global | 240 | 1 |
| The US | 241 | 1 |
| Europe | 242 | 1 |
| ROW | 243 | 1 |
| Annual Cost of Therapy | 244 | 1 |
| Global | 244 | 1 |
| The US | 245 | 1 |
| Europe | 246 | 1 |
| ROW | 247 | 1 |
| Revenue | 248 | 1 |
| Global | 248 | 1 |
| The US | 249 | 1 |
| Europe | 250 | 1 |
| ROW | 251 | 1 |
| Pipeline Molecules | 252 | 1 |
| Phase III | 252 | 2 |
| Phase II | 254 | 5 |
| Phase I | 259 | 1 |
| Preclinical/Discovery Phase | 260 | 1 |
| Immunomodulators Market to 2017 - Competitive Landscape | 261 | 12 |
| Market Share Analysis | 261 | 1 |
| Major Companies | 261 | 1 |
| Hoffmann-La Roche Ltd Roche | 262 | 1 |
| Company Profile | 262 | 1 |
| Marketed Products | 262 | 1 |
| SWOT Analysis | 263 | 1 |
| Amgen Inc | 263 | 1 |
| Company Profile | 263 | 1 |
| Marketed Products | 263 | 1 |
| SWOT Analysis | 264 | 1 |
| Abbott Laboratories | 264 | 1 |
| Company Profile | 264 | 1 |
| Marketed Products | 264 | 1 |
| SWOT Analysis | 265 | 1 |
| Johnson &Johnson | 265 | 1 |
| Company Profile | 265 | 1 |
| Marketed Products | 265 | 1 |
| SWOT Analysis | 266 | 1 |
| Novartis AG | 266 | 1 |
| Company Profile | 266 | 1 |
| Marketed Products | 267 | 1 |
| SWOT Analysis | 267 | 1 |
| Biogen Idec | 268 | 1 |
| Company Profile | 268 | 1 |
| Marketed Products | 268 | 1 |
| SWOT Analysis | 268 | 1 |
| Merck &Co Inc | 269 | 1 |
| Company Profile | 269 | 1 |
| Marketed Products | 269 | 1 |
| SWOT Analysis | 270 | 1 |
| Bristol Myers Squibb Company | 270 | 1 |
| Company Profile | 270 | 1 |
| Marketed Products | 270 | 1 |